MedTrace Logo

Use of Low-dose Molecular Breast Imaging for the Detection of Small Breast Lesions

NCT01285440 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2017-11-09

No results posted yet for this study

Summary

The purpose of this study is to show that improvements in the molecular breast imaging (MBI) technology will allow reduction of the administered dose of Tc-99m sestamibi while maintaining a sensitivity of 90% for tumor detection.

Conditions

  • Suspicious Breast Lesion for Which Biopsy is Scheduled

Sponsors & Collaborators

Principal Investigators

  • Carrie B Hruska, PhD R-D · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2016-12-01
Completion
2016-12-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285440 on ClinicalTrials.gov